Tags

Type your tag names separated by a space and hit enter

Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Lipids 2007; 42(2):109-15L

Abstract

The objective of the study was to evaluate potential benefits of docosahexaenoic acid (DHA) rich fish oil supplementation as an adjunct to statin therapy for hyperlipidaemia. A total of 45 hyperlipidaemic patients on stable statin therapy with persistent elevation of plasma triglycerides (averaging 2.2 mmol/L) were randomised to take 4 g/day (n = 15) or 8 g/day (n = 15) of tuna oil or olive oil (placebo, n = 15) for 6 months. Plasma lipids, blood pressure and arterial compliance were assessed initially and after 3 and 6 months in 40 subjects who completed the trial. Plasma triglycerides were reduced 27% by 8 g/day DHA-rich fish oil (P < 0.05) but not by 4 g/day when compared with the placebo and this reduction was achieved by 3 months and was sustained at 6 months. Even though total cholesterol was already well controlled by the statin treatment (mean initial level 4.5 mmol/L), there was a further dose-dependent reduction with fish oil supplementation (r = -0.344, P < 0.05). The extent of total cholesterol reduction correlated (r = -0.44) with the initial total cholesterol levels (P < 0.005). In the subset with initial plasma cholesterol above 3.8 mmol/L, plasma very low density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) were isolated and assayed for cholesterol and apolipoprotein B (apoB) at the commencement of the trial and at 3 months of intervention. Fish oil tended to lower cholesterol and apoB in VLDL and raise both in LDL. There were no changes in IDL cholesterol, IDL apoB and high-density lipoprotein cholesterol. The results demonstrate that DHA-rich fish oil supplementation (2.16 g DHA/day) can improve plasma lipids in a dose-dependent manner in patients taking statins and these changes were achieved by 3 months. Fish oil in addition to statin therapy may be preferable to drug combinations for the treatment of combined hyperlipidaemia.

Authors+Show Affiliations

School of Health Sciences, University of Wollongong, Wollongong, NSW, Australia. bmeyer@uow.edu.au

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17393216

Citation

Meyer, Barbara J., et al. "Dose-dependent Effects of Docosahexaenoic Acid Supplementation On Blood Lipids in Statin-treated Hyperlipidaemic Subjects." Lipids, vol. 42, no. 2, 2007, pp. 109-15.
Meyer BJ, Hammervold T, Rustan AC, et al. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids. 2007;42(2):109-15.
Meyer, B. J., Hammervold, T., Rustan, A. C., & Howe, P. R. (2007). Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids, 42(2), pp. 109-15.
Meyer BJ, et al. Dose-dependent Effects of Docosahexaenoic Acid Supplementation On Blood Lipids in Statin-treated Hyperlipidaemic Subjects. Lipids. 2007;42(2):109-15. PubMed PMID: 17393216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. AU - Meyer,Barbara J, AU - Hammervold,Tone, AU - Rustan,Arild Chr, AU - Howe,Peter R C, Y1 - 2007/02/08/ PY - 2006/05/23/received PY - 2006/12/14/accepted PY - 2007/3/30/pubmed PY - 2007/8/7/medline PY - 2007/3/30/entrez SP - 109 EP - 15 JF - Lipids JO - Lipids VL - 42 IS - 2 N2 - The objective of the study was to evaluate potential benefits of docosahexaenoic acid (DHA) rich fish oil supplementation as an adjunct to statin therapy for hyperlipidaemia. A total of 45 hyperlipidaemic patients on stable statin therapy with persistent elevation of plasma triglycerides (averaging 2.2 mmol/L) were randomised to take 4 g/day (n = 15) or 8 g/day (n = 15) of tuna oil or olive oil (placebo, n = 15) for 6 months. Plasma lipids, blood pressure and arterial compliance were assessed initially and after 3 and 6 months in 40 subjects who completed the trial. Plasma triglycerides were reduced 27% by 8 g/day DHA-rich fish oil (P < 0.05) but not by 4 g/day when compared with the placebo and this reduction was achieved by 3 months and was sustained at 6 months. Even though total cholesterol was already well controlled by the statin treatment (mean initial level 4.5 mmol/L), there was a further dose-dependent reduction with fish oil supplementation (r = -0.344, P < 0.05). The extent of total cholesterol reduction correlated (r = -0.44) with the initial total cholesterol levels (P < 0.005). In the subset with initial plasma cholesterol above 3.8 mmol/L, plasma very low density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) were isolated and assayed for cholesterol and apolipoprotein B (apoB) at the commencement of the trial and at 3 months of intervention. Fish oil tended to lower cholesterol and apoB in VLDL and raise both in LDL. There were no changes in IDL cholesterol, IDL apoB and high-density lipoprotein cholesterol. The results demonstrate that DHA-rich fish oil supplementation (2.16 g DHA/day) can improve plasma lipids in a dose-dependent manner in patients taking statins and these changes were achieved by 3 months. Fish oil in addition to statin therapy may be preferable to drug combinations for the treatment of combined hyperlipidaemia. SN - 0024-4201 UR - https://www.unboundmedicine.com/medline/citation/17393216/Dose_dependent_effects_of_docosahexaenoic_acid_supplementation_on_blood_lipids_in_statin_treated_hyperlipidaemic_subjects_ L2 - https://link.springer.com/article/10.1007/s11745-006-3014-4 DB - PRIME DP - Unbound Medicine ER -